Biotech News

Milestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Clinical readout

Launch of CARDAMYST ® (etripamil) nasal spray marked by steady prescription growth, new prescriber expansion and improving commercial coverage Company is reducing operating expenses by approximately 30% while prioritizing sales force efforts for CARDAMYST; expects cash runway into late 2028

Related news

MISTMilestone Pharmaceuticals Inc.2026-09-24 12:00 EST

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

MISTMilestone Pharmaceuticals Inc.2026-08-21 12:00 EST

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

LXRXLexicon Pharmaceuticals2026-08-24 12:30 EST

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

RYTMRhythm Pharmaceuticals2026-07-08 21:07 EST

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

LXRXLexicon Pharmaceuticals2026-10-23 12:30 EST

Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

RYTMRhythm Pharmaceuticals2026-08-04 10:55 EST

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

SGMTSagimet Biosciences2026-10-09 11:00 EST

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

ALTAltimmune2026-11-09 17:30 EST

Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder

MLYSMineralys Therapeutics2026-10-22 22:40 EST

Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

SGMTSagimet Biosciences2026-10-22 11:00 EST

Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal...

Recent company news

Stock data

Close
0.40 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States